|
07.01.09
KAI Pharmaceuticals Acquires Progen Patents
VentureWire
KAI Pharmaceuticals Inc. has purchased a collection of patents from publicly traded Progen Pharmaceuticals Ltd. related to the delivery of KAI's peptide therapeutics.
06.30.09
KAI Pharmaceuticals Acquires Patents from Progen, Broadening KAI’s Intellectual Property Estate Covering Peptide-Based Therapies
press release
SOUTH SAN FRANCISCO, Calif., June 30, 2009 -- KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced today the acquisition of an extensive collection of issued and pending patents from Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq:PGLA), a globally focused biotechnology company. The patents claim compositions and methods related to transporter molecules that can deliver compounds, including peptides such as those being developed in the KAI pipeline, across biological membranes and into cells. Terms of the agreement were not disclosed.
06.30.09
AGTC and National Neurovision Research Institute Collaborate, Funding Research in two Genetic Retinal Diseases
Press Release
Combined Funds and Resources to Be Used to Further Demonstrate the AGTC’s AAV System’s Ability to Deliver Sustainable Treatments for Human Retinal Diseases GAINESVILLE, Fla.--(BUSINESS WIRE)--Applied Genetic Technologies Corporation (AGTC), a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that AGTC has entered into an agreement with the National Neurovision Research Institute (NNRI), the clinical trial support organization for the Foundation Fighting Blindness(FFB), to collaborate in experiments using the AAV delivery system in the treatment of two genetic retinal diseases known to cause blindness at an early age. The research will be coordinated by AGTC and will be conducted at The University of Florida, Oregon Health & Science University, The University of Pennsylvania, and The University of British Columbia.
06.30.09
Biolex Therapeutics Announces Completion of Enrollment in SELECT-2 Phase 2b Trial of Locteron(R) in Chronic Hepatitis C
press release
PITTSBORO, NC--(Marketwire - June 29, 2009) - Biolex Therapeutics, Inc. announced today that it has completed patient enrollment in the SELECT-2 Phase 2b trial of its lead product candidate Locteron® for the treatment of chronic hepatitis C. Locteron, controlled-release interferon alpha 2b, is designed to improve patient care by providing a more convenient once-every-two week dosing schedule and by reducing the side effects, including flu-like symptoms, associated with pegylated interferons, the current standard of care.
06.24.09
SENTILLION AND MICROSOFT SIGN SOFTWARE LICENSING AGREEMENT TO STREAMLINE ACCESS TO HEALTH DATA
Press Release
Microsoft’s Amalga Unified Intelligence System Achieves Seamless Clinical Workflow By Embedding Sentillion’s Single Sign-On and Context Management Technology ANDOVER, MA – June 23, 2009 – Sentillion, Inc. announced today that it has signed a licensing agreement with Microsoft Corp. in which Sentillion will supply its single sign-on (SSO) and context management technology to become a featured module of Microsoft Amalga Unified Intelligence System (UIS) 2009.
06.10.09
Durham company banking on solar
News & Observer
Durham semiconductor company Semprius is developing what it hopes will become the next generation of solar-energy devices with the help of $6.4 million in new venture capital.
06.09.09
Proteon Founders Nicholas Franano, M.D. and William P. Whitaker, Esq. Named Ernst & Young Entrepreneur Of The Year® 2009 Award Winners in the Central Midwest Region
Press Release
Kansas City, MO, June 9, 2009 – Proteon Therapeutics, Inc., today announced that founders Nicholas Franano, M.D. and William P. Whitaker, Esq. received Ernst & Young Entrepreneur Of The Year® 2009 Awards in the Private Equity/Venture Capital Backed category in the Central Midwest region. According to Ernst & Young LLP, the award recognizes outstanding entrepreneurs who are building and leading dynamic growing businesses. Dr. Franano and Mr. Whitaker were selected by an independent panel of judges, and the award was presented at a gala event at the Sheraton Overland Park Hotel on Thursday, June 4, 2009.
05.28.09
Proteon Therapeutics Extends Cash Runway With Series B Bump
Dow Jones VentureWire
Biopharmaceutical company Proteon Therapeutics Inc., which in March simultaneously raised a Series B round and formed a deal with Novartis AG for the potential sale of the company, has extended that round to $50 million.
05.14.09
Cempra Pharmaceuticals Closes $46 Million Series C Financing
Business Wire
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Cempra Pharmaceuticals, Inc., a clinical-stage company developing novel antibiotics for difficult-to-treat and drug-resistant infections, announced today that it has successfully raised $46 million in a Series C financing.
05.04.09
Arsenal Medical Armed With $8M From Insiders
Dow Jones VentureWire
Arsenal Medical Inc., a stealth-mode medical device company previously known as WMR Biomedical Inc., has raised $8.1 million in an insider Series C round.
05.04.09
Applied Genetic Stays Inside To Guard Valuation
Dow Jones VentureWire
Guarding its valuation against potential new investors, Applied Genetic Technologies Corp. has added $11.8 million in insider funding to its Series A round to pursue clinical data for its treatments targeted at the un-commercialized area of gene therapy.
05.01.09
Applied Genetic Technologies adds $11.8M round to its DNA
TechJournal South
GAINSVILLE, FL - May 1, 2009 - Applied Genetic Technologies Corp., a clinical stage biotechnology company has closed on an $11,800,000 financing round led by InterWest Partners of Menlo Park, CA. Other participants in the round include Intersouth Partners and MedImmune Ventures Inc.
05.01.09
Argos Therapeutics sees new promise for immunotherapeutics
TechJournal South
DURHAM, NC— May 1, 2009 - Argos Therapeutics believes the success of Seattle-based Dendreon Corp.’s Phase 3 study of immunotherapy PROVENGE, which significantly prolonged the survival of patients with advanced prostate cancer, points out the potential for immunotherapeutics such as its own to tackle cancer and HIV.
04.28.09
Mixx Looks to Go Beyond the News
The Washington Post
The McLean-based news site Mixx.com is hoping to persuade consumer product developers to draw on the wisdom of the Web as it launches a service today that pairs its online community of news junkies with companies wanting to bounce ideas off a test audience.
04.24.09
Biolex Therapeutics Researchers Present Locteron(R) U.S. Phase 2a Hepatitis C Trial Results at EASL Conference
Press Release
PITTSBORO, NC--(Marketwire - April 24, 2009) - Biolex Therapeutics, Inc. announced that the results from its United States Phase 2a clinical trial (the "PLUS" trial) of Locteron® will be presented today at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark. Locteron, controlled-release interferon alpha 2b, is designed to improve patient care by providing a more convenient once-every-two week dosing schedule and by reducing the side effects, including flu-like symptoms, associated with pegylated interferons, the current standard of care. Biolex announced earlier this week the commencement of patient dosing in the SELECT-2, a Phase 2b trial of Locteron in the United States and Europe.
04.24.09
Bright View gets $4 million assist
News & Observer
Bright View Technologies has raised $4 million to boost the manufacturing and marketing of its first products.
04.22.09
Bright View Lights Up With $4M Round
Dow Jones VentureWire
Microstructure-based optical film manufacturer Bright View Technologies Inc. has raised $4 million in its latest round of funding.
04.22.09
Bright View Technologies lights up with $4M round
Tech Journal South
MORRISVILLE, NC - Bright View Technologies Inc., a developer of advanced optical films for LED display applications, has raised $4 million in a round led by Durham-based Intersouth Partners.
04.20.09
Biolex Therapeutics Commences Phase 2B Trial of Locteron(R) in Chronic Hepatitis C
Press Release
PITTSBORO, NC--(Marketwire - April 20, 2009) - Biolex Therapeutics, Inc. announced today the commencement of patient dosing in the SELECT-2 Phase 2b trial of its lead product candidate Locteron for the treatment of chronic hepatitis C. Locteron, controlled-release interferon alpha 2b, is designed to improve patient care by providing a more convenient once-every-two week dosing schedule and by reducing the side effects associated with pegylated interferons, the current standard of care, including flu-like symptoms. The Company also announced that the preliminary results of the recently completed United States Phase 2a Locteron trial ("PLUS" trial) will be presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) April 24, 2009 in Copenhagen, Denmark. The Phase 2b trial is being conducted in the United States and Europe in 100 treatment-naïve, genotype-1, chronic hepatitis C patients. Patients will be randomized into one of four dosing cohorts,
04.13.09
Start-Up Clarabridge Takes the Capital and Scores
Washington Post
Ted Leonsis a few years back provided the best description of venture capital that I ever heard. The former AOL mogul compared the exercise of investing in start-ups to drafting hockey players for his Washington Capitals.
04.08.09
KAI Pharmaceuticals Initiates Third Phase 2a Study in Program to Develop KAI-1678 for the Treatment of Neuropathic Pain
Press Release
South San Francisco, CA — April 8, 2009 — KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has initiated a third Phase 2a study of KAI-1678, a first-in-class, isozyme-selective, small peptide inhibitor of the epsilon protein kinase C pathway (epsilon PKC). The study has begun enrollment of patients for the treatment of chronic neuropathic pain associated with spinal cord injury (SCI). In December 2008, KAI announced the initiation of its first Phase 2a study of KAI-1678 in patients with moderate-to-severe postoperative pain following total hip or total knee replacement. A second Phase 2a trial in patients with chronic postherpetic neuralgia was initiated last month.
04.08.09
Alimera Sciences' Iluvien™ Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
Press Release
ATLANTA, April 8, 2009 – Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that an independent Data Safety Monitoring Board (DSMB) has recommended the continuation of two pivotal Phase 3 clinical trials for the use of Iluvien™ in the treatment of diabetic macular edema (DME) under the current protocol, without change.
04.03.09
KAI Pharmaceuticals Expands KAI-1678 Development Program, Initiating a Phase 2a Study for Neuropathic Pain
Press Release
South San Francisco, CA — March 31, 2009 — KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has initiated a second Phase 2a study of KAI-1678, a first-in-class, isozyme-selective, small peptide inhibitor of the epsilon protein kinase C pathway (epsilon PKC). The study has begun enrollment of patients for the treatment of chronic neuropathic pain associated with chronic postherpetic neuralgia (PHN). In December 2008, KAI announced the initiation of its first Phase 2a study of KAI-1678 in patients with moderate-to-severe postoperative pain following total hip or
03.10.09
Proteon Inks Deal For Equity, Novartis Sale Option
Dow Jones VentureWire
Renal and vascular disease treatment developer Proteon Therapeutics Inc. has raised a $38 million Series B round and formed an exclusive option agreement with Novartis AG for the possible sale of the company.
03.06.09
Proteon Therpapeutics Raises $38 Million, Signs Acquisition Option
peHUB
Proteon Therapeutics, a Waltham, Mass.-based drug developer based in vascular and kidney disease, has raised $38 million in Series B funding. MPM Capital led the round, and was joined by Vectis Healthcare & Life Sciences Fund and return backers TVM Capital, Skyline Ventures, Prism VentureWorks and Intersouth Partners.
03.05.09
Proteon Therapeutics Completes $38M Equity Financing
Press Release
Waltham, Mass., March 5, 2009 — Proteon Therapeutics, Inc., announced today that it has successfully completed a $38 million Series B equity financing, led by MPM Capital on behalf of the MPM Bio IV NVS Strategic Fund L.P.
02.17.09
Sentillion Announces 2008 as the Best Year in the Company’s History
Press Release
Signs 30 New Customers; Reaches 400,000 Live User Milestone; Named #1 SSO Vendor in Healthcare ANDOVER, MA – February 17, 2009 – Sentillion, whose identity and access management (IAM) solutions are the most widely implemented in healthcare, today announced that 2008 marked the best performance in the Company’s history. In 2008, Sentillion signed 30 new customers, representing over 500,000 new user licenses. In addition, the Company reached an unprecedented industry milestone of 400,000 live users and for the second consecutive year, Vergence® was named the number one Single Sign-On product in the 2008 Top 20 Best in KLAS Awards: Software & Professional Services report.
02.02.09
Ziptronix Builds Up With $1.8M Tranche
Dow Jones VentureWire
Ziptronix Inc., a developer of technology to bond semiconductors vertically, has secured the second tranche of its Series 1 recapitalization as it senses opportunity in struggling equipment makers.
01.30.09
Web Security Co. Purewire Grabs Opinity's IP
Dow Jones VentureWire
Purewire Inc., provider of an on-demand secure Web gateway, has acquired the intellectual property of online reputation services company Opinity Inc.
01.26.09
Clarabridge Marks Another Banner Year
Press Release
Reston, Va. (January 26, 2009) — Clarabridge, the leading provider of text mining software used by many Global 1000 companies to improve customer experience management (CEM), today announced it has tripled revenue in 2008, making it the fastest-growing company in its space.
12.16.08
Overture Networks Acquires Ceterus Networks to Fuel Expansion
Press Release
RESEARCH TRIANGLE PARK, NC, DECEMBER 16, 2008 – Overture Networks, the industry’s trusted Carrier Ethernet solutions provider, today announced the acquisition of Richardson, TX-based Ceterus Networks. The addition of the Ceterus product family, which includes the industry’s newest and most full-featured optical Ethernet access solutions for cell site backhaul, complements Overture’s leadership in business services solutions. The new company creates a clear market leader in multiple, high-growth Carrier Ethernet segments and provides network service providers a complete line of Carrier Ethernet edge and aggregation systems.
12.04.08
TapRoot Announces WalkingHotSpot Distribution Deal with Handango
Press Release
RESEARCH TRIANGLE PARK, N.C. -12-04-2008 - TapRoot Systems, Inc., a leading developer of software solutions for the smartphone market announced a distribution agreement with Handango Inc., the leading retailer of smartphone applications. The agreement provides Handango a worldwide license to distribute TapRoot's award winning WalkingHotSpot throughout Handango's numerous distribution channels.
11.21.08
SciQuest Awarded Software Company of the Year and Technology Executive of the Year
Press Release
CARY, N.C. – SciQuest, Inc., the global leader empowering enterprises to realize the potential of strategic procurement, today announced that the company and president and CEO Stephen Wiehe were recognized by the North Carolina Technology Association (NCTA) with two awards: Software Company of the Year and Technology Executive of the Year.
11.21.08
Argos Therapeutics Completes $35.2 Million Series C Financing
Press Release
Argos Therapeutics today announced the closing of the second and final tranche of a $35.2 million Series C financing from a top-tier, international syndicate of new and existing investors. The first tranche was completed in April 2008.
11.20.08
Aldagen Announces Positive Phase1/2 Results for Critical Limb Ischemia Stem Cell Therapy ALD-301
Press Release
Durham, NC – November 20, 2008 — Aldagen today announced positive results from its multicenter Phase 1/2 clinical trial of ALD-301, a novel stem cell therapy being developed for the treatment of critical limb ischemia. In the 24-week Phase 1/2 trial, ALD-301 was well tolerated. Importantly, the study results also indicated that during the 12-week efficacy assessment period, there were improvements in overall clinical status as well as increased blood flow in the affected limb in the group of patients treated with ALD-301.
11.19.08
Overture Networks Embraces Environmental Responsibility
press release
RESEARCH TRIANGLE PARK, NC — Overture Networks, the industry’s trusted Carrier Ethernet solutions provider, has announced several initiatives that the company has implemented as part of its efforts to reduce its carbon footprint. New packaging, smarter use of resources and increased support for its customers’ own energy-reduction efforts are just a few of the ways Overture Networks is “going green.”
11.19.08
KAI Reports Positive Preclinical Results for KAI-1678, First-in-Class Compound to Treat Pain
Press release
SOUTH SAN FRANCISCO, Calif., November 19, 2008—KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced preclinical results demonstrating the effectiveness of KAI-1678 in reversing pain (hyperalgesia and allodynia) in multiple preclinical models. KAI-1678 also was shown to reverse pain more effectively than gabapentin, an industry-standard comparison in pain research. The preclinical results were presented in two posters at Neuroscience 2008, the 38th annual meeting of the Society for Neuroscience, taking place in Washington, DC from November 15 - 19. KAI-1678, a first-in-class, isozyme-selective, small peptide inhibitor of the epsilon protein kinase C pathway (epsilon PKC), is expected to enter Phase 2a clinical testing by the end of 2008.
11.18.08
Ziptronix CEO Highlights Crucial Role of Low Temperature Bonding
Press Release
Burlingame, Ca. - The future success of the semiconductor industry will depend on how successful it is in implementing 3D IC technology to meet the demands of a 17-year-old consumer named Jeremy, according to Ziptronix CEO Dan Donabedian. In a presentation at the fifth annual 3D Architectures for Semiconductor Integration and Packaging conference today in Burlingame, CA, Donabedian described the role his company's revolutionary bonding technology will play in the emerging 3D IC supply chain.
11.13.08
SciQuest Announces Strategic Alliance with QIAGEN
Press Release
CARY, N.C. – November 12, 2008 - SciQuest, Inc., the global leader empowering enterprises to realize the potential of strategic procurement, today announced the formation of a strategic alliance with QIAGEN, the leading provider of sample and assay technologies. Through the alliance, both companies will work together to help QIAGEN's customers realize the efficiencies of procurement automation through faster, easier access to crucial diagnostics and research supplies.
11.11.08
siXis, Inc. Introduces Reconfigurable Computing Platform
Press Release
RESEARCH TRIANGLE PARK, N.C. –November 11, 2008- siXis, Inc., a semiconductor company focused on commercializing its Silicon Circuit Board (SiCB) technology, introduced its first product today, the SX1000 Reconfigurable Computing Platform. The SX1000, based on field-programmable gate array (FPGA) technology, provides desktop supercomputing power and is modular and extremely scalable. Utilizing SiCB technology, the SX1000 is significantly smaller, provides higher performance, uses less power and generates less heat than any other high performance reconfigurable computing system available today.
11.10.08
Overture Networks Honored With Triangle Business Journal’s Fast 50 Award
Press Release
RESEARCH TRIANGLE PARK, N.C. -11-10-2008 - Overture Networks, the industry’s trusted Carrier Ethernet solutions provider, today announced it has received the Triangle Business Journal’s 2008 Fast 50 Award, which recognizes the 50 fastest growing private companies in the Triangle. Overture Networks made its debut on the list with an impressive 13th place ranking that was made possible by strong sales and corporate expansion in 2008.
11.06.08
Aldagen and UC Davis Form Collaboration Related to Neural Diseases
Press Release
DURHAM, NC--(Marketwire - November 6, 2008) - Aldagen, a North Carolina biopharmaceutical company developing proprietary regenerative cell therapies, and UC Davis Health System will collaborate to explore the activity of Aldagen's unique adult stem cell population in a preclinical model of ischemic stroke. Adult stem cells hold promise in the treatment of this condition and other neurological disorders, including Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury and cerebral palsy.
11.03.08
Biolex Therapeutics Adds Two Drug Development Executives to Accelerate Development of Locteron(R) in Hepatitis C
press release
PITTSBORO, NC--(Marketwire - November 03, 2008) - Biolex Therapeutics, Inc. announced that Walker Long, M.D. has joined the Company as Chief Medical Officer and Vice President, Drug Development, and that Anne McKay has joined as Vice President, Regulatory Affairs. Each of these pharmaceutical executives brings a proven track record in drug development and complement the experienced management team already in place. The Company also announced that it has promoted Bipin Dalmia, Ph.D., MBA, to Senior Vice President, Business Development and Intellectual Property.
11.03.08
Viamet Pharma Tops Off Series A At $6.25M
Dow Jones Venture wWre
Infectious disease treatment developer Viamet Pharmaceuticals Inc. has raised a total of $6.25 million in Series A funding after closing a second tranche of the round in August.
10.30.08
Aldagen Receives Orphan Drug Designation for ALD-101
Press Release
- ALD-101, a novel stem cell therapy, is currently in Phase 3 trial – Durham, NC – October 29, 2008 – Aldagen, Inc. today announced that it has received orphan drug designation for ALD-101 from the U.S. Food and Drug Administration (FDA). The designation was granted for the use of ALD-101 to improve patient outcomes by decreasing time to platelet and neutrophil engraftment in patients with inherited metabolic disorders undergoing umbilical cord blood transplantation.
10.28.08
Argos Therapeutics Publishes Approach to Generating High-Avidity Cytotoxic T Cells with Dendritic Cell-Based Immunotherapy
Press Release
DURHAM, N.C. -- Argos Therapeutics today announced the publication of a paper in the October 15th issue of the Journal of Immunonology demonstrating that the Company’s proprietary RNA-electroporated dendritic cells generate high-avidity cytotoxic T cells (CTL) in vitro that are able to destroy cells expressing their target antigens. This advance may potentially improve the clinical benefit of dendritic cell-based immunotherapies for the treatment of infectious disease and cancer. This approach is part of the Company’s Arcelis™ technology, a proprietary platform for creating personalized immunotherapies for HIV, other infectious diseases, and cancer.
10.28.08
Argos Therapeutics Publishes Novel Approach to Improving Stimulation of Immunotherapeutic Pathways via Dendritic Cells
press release
DURHAM, N.C. -- Argos Therapeutics today announced the publication of an article in the online journal BMC Molecular Biology supporting the Company’s novel method of stimulating the CD40 receptor signal cascade in dendritic cells (DCs), which may potentially improve the potency of their DC-based immunotherapy. Argos’ process involves electroporation of RNA into DCs, encoding a modified version of the T-cell protein CD40L. Stimulating this receptor signal cascade through ectopic expression of this novel CD40L RNA results in secretion of the downstream inflammatory cytokine IL-12 from the electroporated DCs. This new approach is part of the Company’s Arcelis™ technology, a proprietary platform for creating personalized immunotherapies for HIV, other infectious diseases, and cancer.
10.28.08
Technical College Systems of GA Deploys Mobile Security
news story
The Technical College System of Georgia has deployed the Purewire Web Security Service for BlackBerry devices. The Technical College System oversees the state's system of 33 technical colleges, adult literacy programs, and a number of economic and workforce development programs.
10.16.08
Aldagen, Inc. Appoints Lyle Hohnke, Ph.D. to Board of Directors
Press Release
Durham, NC – October 15, 2008 – Aldagen, Inc. today announced the appointment of Lyle Hohnke, Ph.D. to its Board of Directors. Dr. Hohnke has over 35 years of health care industry experience, focusing on biotechnology, pharmaceuticals and medical devices. He has been a partner of Tullis Dickerson, a healthcare focused venture capital fund, since 1994 and currently serves on the board of several private and public companies.
10.16.08
SciQuest Brings Procurement Functionality to the Kuali Foundation
Press Release
CARY, N.C. -- SciQuest, Inc., the global leader empowering enterprises to realize the potential of strategic procurement, today announced that the company will serve as a commercial affiliate of the Kuali Foundation, a not-for-profit organization that coordinates the efforts of colleges and universities to sustain and evolve a comprehensive portfolio of enterprise software applications. Originating from Indiana University and based on open-source and community-source principles, the Kuali Foundation is comprised of more than 200 institutions worldwide.
10.10.08
Argos Therapeutics Publishes Approach to Improving Dendritic Cell-Based Immunotherapy
Press Release
DURHAM, N.C. -- Argos Therapeutics today announced the publication of a paper in the October 2008 issue of the Journal of Immunotherapy demonstrating that the Company’s process of maturing dendritic cells (DC) electroporated with antigen-encoded messenger RNA (mRNA) is capable of driving long-term, stable expansion of cytolytic antigen-specific T cells that express effector/memory phenotype. These T cells also exhibited much higher functional activity, suggesting improved T cell avidity. This approach is part of the Company’s Arcelis™ technology, a proprietary platform for creating personalized immunotherapies for HIV, other infectious diseases, and cancer.
10.10.08
Zenoss Announces Record Quarterly Customer Growth Amid Struggling Economy
Press release
ANNAPOLIS, MD--(Marketwire - October 8, 2008) - Zenoss Inc., a leading provider of commercial open source application, systems, and network management software, today announced it achieved record sales during the third quarter of 2008. While IT budgets continue to pull back in the wake of the global economic slow down, the rapidly-growing software firm grew 85 percent quarter over quarter, adding over 35 new commercial customers including large financial institutions, Fortune 500 companies, leading web-based companies and branches of the US Armed Forces. To date, Zenoss' solution has been installed in 175 countries by over 18,000 organizations around the world.
10.08.08
Aldagen Withdraws IPO Due To Market Conditions
News Story
Aldagen Inc., a Durham, N.C., biopharmaceutical company, on Tuesday withdrew its planned initial public offering with the Securities and Exchange Commission due to market conditions.
10.07.08
Biolex Adds $60M, Secures Drug Rights
Dow Jones
After pulling plans for an initial public offering earlier this year, biopharmaceutical company Biolex Therapeutics Inc. is moving forward with a new $60 million Series D financing round and the acquisition of the rest of the rights to its lead treatment.
10.07.08
Pittsboro biotech raises money
News & Observer
Biolex Therapeutics, which earlier this year scrapped plans to sell stock to the public, has rebounded in a big way by raising $60 million from private investors.
10.06.08
siXis, Inc. Launches New Identity
Press Release
RESEARCH TRIANGLE PARK, NC – October 6, 2008 – siXis, Inc., a semiconductor company previously known as Beeco, Inc., announced today its new name and the launch of its new identity.
10.01.08
3-D Startup Is Ahead of Its Time
news story
As the 3-D integration infrastructure evolves, it is becoming clear that low-cost, reliable bonding technology is required for 3-D IC integration to become mainstream. Without question, the industry is looking for solutions with lower cost of ownership (CoO). Ziptronix CEO Dan Donabedian thinks his company's time has come.
10.01.08
Alimera Reports Results From the Six-month Interim Readout of the Human PK Iluvien™ Study
Press Release
ATLANTA, October 1, 2008 -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim month six safety and efficacy results from the first human pharmacokinetic (PK) study of Iluvien™.
09.30.08
Cempra Pharmaceuticals and Biovista Enter Agreement for Macrolide Clinical Trial Design Support Studies
Press release
CHAPEL HILL, N.C. & CHARLOTTESVILLE, Va. -- 09-30-2008 – Cempra Pharmaceuticals, Inc., and Biovista, Inc., announced today that they have entered into a research agreement to systematically identify and profile adverse event associations for members of the macrolide drug class. The data generated will be used to better understand the unique benefit/risk characteristics of this important group of antimicrobial drugs, thereby helping to adapt and optimize future clinical trial designs.
09.30.08
Nitronex Releases 5.1 - 5.8GHz Performance Data on its 5W GaN-on-Si RF Power Transistor
Press release
CHICAGO - WiMAX World, Booth #923, (September 30, 2008) - Nitronex, the global leader in gallium nitride on silicon (GaN-on-Si) RF power transistors for the wireless infrastructure, broadband and military markets, has expanded the performance data of its 28V, 5W class high electron mobility transistor (HEMT) to include frequencies between 5.1 - 5.2GHz and 5.7 - 5.8GHz. Designated the NPTB00004, it achieves 27 dBm (400mW) average output power at 2% EVM in 5.2 GHz WiMAX systems, and 28 dBm (630mW) average output power at 2% EVM in 5.8 GHz WiMAX systems (single carrier OFDM, 64-QAM ¾, 8 burst, 20ms frame, 15ms frame data, 3.5MHz channel bandwidth, peak/avg = 10.3dB).
09.24.08
DSMB Again Supports Continuation of Alimera Sciences’ Phase 3 Clinical Trial of Iluvien™ for the Treatment of DME
Press Release
ATLANTA, September 24, 2008 – Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has again recommended that the two pivotal Phase 3 clinical trials for the use of Iluvien™ in the treatment of diabetic macular edema (DME) continue under the current protocol, without change.
09.10.08
Proteon Receives FDA Fast Track Designation For First Drug Candidate PRT–201
Press Release
Waltham, Mass., September 10, 2008 — Proteon Therapeutics, Inc., announced today it has received Food and Drug Administration (FDA) fast track designation for the development program for PRT-201. PRT-201 is being investigated for its ability to improve vascular access in patients currently on or being prepared for hemodialysis. The fast track designation is intended to facilitate development and expedite review for drugs that treat serious diseases and fill unmet medical needs.
09.09.08
Zenoss Core Recognized as Best Open Source Network Monitoring Solution
Press Release
Annapolis, MD (August 21, 2008) – Zenoss Core has been awarded the InfoWorld Best of Open Source Software Award in the Network Monitoring category. The InfoWorld judges cited Zenoss Core’s “unified, object-based repository of infrastructure monitoring,” and “tightly integrated tools and reports,” as reasons for selecting Zenoss Core as the leading open source solution for network monitoring. The Zenoss Core project is sponsored and developed by Zenoss, Inc. a leading provider of open source network, systems and application management software.
09.09.08
WalkingHotSpot Now Commercially Available for smartphone users globally
Press Release
RESEARCH TRIANGLE PARK, NC – September 8, 2008 – TapRoot Systems Inc., a leading developer of software solutions for the smartphone market, today announced that its “always-with-you” WalkingHotSpot™ internet connectivity solution is available for all consumers to purchase directly from www.walkinghotspot.com.
09.03.08
TapRoot Systems, Inc. Supports Wi-Fi Protected Setup™ in Microsoft Windows Mobile Phones
Press Release
RESEARCH TRIANGLE PARK, N.C. -- TapRoot Systems Inc., a leading developer of software for the smartphone market, announced their support for Wi-Fi Protected Setup™ in its rich set of embedded 802.11 Wireless LAN software products. TapRoot’s WLAN software solutions enable mobile device OEM’s and ODM’s to take advantage of advanced Microsoft Windows Mobile features and meet mobile operator requirements.
08.27.08
Ziptronix Pioneering 3D Integrated Circuit Process Technology
I-Micronews
Founded in October 2000, Ziptronix , spun out of North Carolina's RTI International for the purpose of commercializing wafer and die bonding technology. Ziptronix has been a pioneer when it comes to 3D IC integration. Ziptronix licenses its processes for both development and production partnerships
08.11.08
Nitronex Awarded Phase II STTR Grant to Further Enhance GaN-on-Silicon HEMTs for High-Frequency Applications
press release
DURHAM, N.C. (August 11, 2008) -- Nitronex, an innovative developer and manufacturer of high-performance RF power transistors for wireless infrastructure, broadband, and military markets, has received Phase II Small Business Technology Transfer (STTR) funding to further develop its GaN technology for military and aerospace applications. The two year Phase II STTR program began in the first quarter of this year. The primary program objective is to deliver high power X-band GaN monolithic microwave integrated circuits (MMICs) that address Ballistic Missile Defense radar needs of the Missile Defense Agency (MDA).
08.11.08
Clarabridge taps in $12M round for text analysis software
TechJounral South
RESTON, VA—Clarabridge, which sells text analysis software used to improve customer relationship management, has raised a $12 million Series C round led by Grotech Ventures with existing investors Harbert Venture Partners, Boulder Ventures, and Intersouth Partners participating.
08.11.08
Argos Therapeutics to Discuss Automated Manufacturing Process for its Arcelis™ Personalized Immunotherapy Platform
press release
DURHAM, N.C. - 08-11-08 - Argos Therapeutics today announced that Dr. Fred Miesowicz, Ph.D., Chief Operating Officer, will present details on the Company’s automated manufacturing process for its Arcelis™ platform, a technology for creating personalized immunotherapies for HIV, other infectious diseases, and cancer. The presentation will take place on August 14, 2008 at the Cambridge Healthtech Institute’s conference on Advances in Cancer Vaccines, part of the ImVacS Immunotherapeutics and Vaccine Summit, in Cambridge, MA.
08.06.08
SciQuest Announces Release of Enhanced Eprocurement and Supplier Enablement Solutions
press release
CARY, N.C. -- SciQuest, Inc., the global leader empowering enterprises to realize the potential of strategic procurement, today announced enhancements to the company's on-demand eprocurement and supplier enablement solution suite. The enhancements included in the August 3rd product release are designed to further streamline the procurement function for SciQuest's customers. Offered through the software-as-a-service (SaaS) model, product releases of SciQuest's on-demand solutions are scheduled three times each year.
08.05.08
Argos Therapeutics’ Arcelis™ Personalized Immunotherapy Platform in HIV Achieves Primary Endpoint in Phase 1 Trial
Press Release
DURHAM, N.C. - August 5, 2008 – Argos Therapeutics today announced the presentation of positive immune response data from a Phase 1 clinical trial of AGS-004 in HIV-infected adults in combination with antiretroviral therapy (ART). AGS-004 achieved the trial’s primary endpoint of induction of T cell response to patient-specific HIV antigens. AGS-004 is a personalized HIV immunotherapy generated by the Company’s Arcelis™ technology. Arcelis is an immunotherapy platform for creating personalized, RNA-loaded dendritic cell-based therapies perfectly matched to each patient’s unique virus. AGS-004 is currently undergoing a Phase 2a proof-of-concept trial. These data were presented in an oral poster discussion on August 5, 2008 at the XVII International AIDS Conference in Mexico City.
07.30.08
SciQuest Named to the 2008 Supply & Demand Chain Executive 100
Press Release
CARY, N.C. - 7-30-08 - SciQuest, Inc., the global leader empowering enterprises to realize the potential of strategic procurement, today announced that the company has been named a Supply & Demand Chain Executive 100 leader in the magazine's June/July 2008 issue. SciQuest once again joins this prestigious list of "next- wave" supply chain leaders.
07.30.08
Switching to software as a service saved SciQuest
TechJournal South
RESEARCH TRIANGLE PARK, NC –Moving SciQuest from a public company offering an online business-to-business exchange to a private one offering software as a service saved the company, says CEO Stephen Wiehe. The company was named the “Best Business Turnaround” in the 2008 American Business Awards – the Stevie Awards.
07.29.08
SciQuest Becomes Key Component in State of Georgia's Vision for Procurement across Statewide Agencies
press release
CHARLOTTE, N.C. - 07-29-2008 - SciQuest, Inc., the global leader empowering enterprises to realize the potential of strategic procurement, announced at the National Institute of Government Purchasing (NIGP) Annual Forum and Expo that the State of Georgia's Department of Administrative Services has chosen SciQuest as part of a multi-million dollar investment in new procurement technologies and processes that will unite statewide entities into one comprehensive buying consortium.
07.24.08
Overture Networks Expands as World Turns to Carrier Ethernet for Next-Generation Communications
Press Release
RESEARCH TRIANGLE PARK, NC — 07-24-2008 – Overture Networks, a leading supplier of converged packet access solutions for Carrier Ethernet, has announced three new additions to its sales team to address the rapidly growing demand for the company’s award-winning product line. Stuart Foladare, Regional Vice President for Major Accounts, Jack Yocum, Regional Vice President for North American Sales and Hubert Gaertner, Accounts Director for Central and Eastern Europe, will play integral roles in expanding Overture Networks’ business as carriers worldwide look to leverage Carrier Ethernet to boost revenues and streamline costs.
07.24.08
Aldagen, Inc. Appoints William E. Evans, PharmD to Board of Directors
Press Release
Dr. Evans is Director and Chief Executive Officer of St. Jude Children’s Research Hospital Durham, NC – July 22, 2008 – Aldagen, Inc. today announced the appointment of William E. Evans, PharmD to its Board of Directors. Dr. Evans has been with St. Jude Children’s Research Hospital since 1973, and began serving as director and chief executive officer in 2004. Dr. Evans’ research at St. Jude Children’s Research Hospital has focused on pediatric diseases and disorders, and he has authored more than 300 articles and book chapters. Dr. Evans has received several national awards for his research, including three consecutive National Institutes of Health MERIT Awards from the National Cancer Institute.
07.21.08
SciQuest Announces Partnership with Lawson Software
Press Release
CARY, N.C. -- SciQuest, Inc., the global leader empowering enterprises to realize the potential of strategic procurement, today announced a partnership with Lawson Software. Lawson serves more than 4,000 customers, including eight of the top 10 integrated health networks and more than 500 healthcare organizations. Lawson also serves more than 120 public services customers, including state and local governments as well as school districts.
[ Show archived stories ]
|
